Article

Cancer targets in the Ras pathway.

Cancer Research Institute, University of California San Francisco Comprehensive Cancer Center, 94115, USA.
Cold Spring Harbor Symposia on Quantitative Biology 02/2005; 70:461-7. DOI: 10.1101/sqb.2005.70.044
Source: PubMed

ABSTRACT Ras proteins play a direct causal role in human cancer and in other diseases. Mutant H-Ras, N-Ras, and K-Ras occur in varying frequencies in different tumor types, for reasons that are not known. Other members of the Ras superfamily may also contribute to cancer. Mutations also occur in downstream pathways, notably B-Raf, PTEN, and PI 3' kinase: These pathways interact at multiple points, including cyclin D1, and act synergistically. In some cases mutations in Ras and effectors are mutually exclusive; in other cases, they coexist. Drugs blocking elements of the pathway are in different stages of clinical development. One of these, the Raf kinase/VEGF-R2 inhibitor Sorafenib, has already been approved for treatment of renal cancer and is being tested in other indications. However, therapeutic targets in the Ras pathway have not yet been fully validated as bona fide targets.

Full-text

Available from: Osamu Tetsu, Mar 16, 2015
1 Follower
 · 
168 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mammalian target of rapamycin (mTOR) plays a key role in regulating cell proliferation, metabolism, and aging, and is activated at a high frequency in various types of cancers by alterations in receptor tyrosine kinases (RTKs), RAS, phosphatidylinositol 3-kinase (PI3K), and AKT. The RTK/RAS/PI3K/AKT/mTOR signaling pathway is broadly activated in endometrial carcinomas through mutations (and/or copy number alterations) of FGFR2 (fibroblast growth factor receptor 2), KRAS, NF1, PTEN, PIK3CA, PIK3R1, PIK3R2, and AKT1. These alterations frequently coexist with the other alterations, especially in tumors with PIK3CA mutations. Although targeting mTOR signaling is a promising therapeutic strategy, single-agent mTOR inhibition showed modest clinical response (response rate PI3K/AKT/mTOR signaling by reviewing integrated genomic analyses and we also explore whether novel therapies targeting this pathway might be clinically approved for endometrial cancer treatment in the future.
    03/2015; 4(1). DOI:10.1007/s13669-014-0103-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are a group of small non-coding RNA molecules that potentially play a critical role in tumorigenesis. Increasing evidences indicate that miR-378-5p is dysregulated in numerous human cancers including colorectal cancer (CRC) which hypothesizes that miR-378-5p may play an important role in tumorigenesis. However, its role in CRC carcinogenesis remains poorly defined because of lacking target genes information. In the present study, it was demonstrated that the expression of miR-378-5p was down-regulated in CRC tissues and cell lines as determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Furthermore, overexpression of miR-378-5p suppressed cell proliferation, as indicated by CCK-8 assay. Flow cytometric analysis demonstrated that overexpression of miR-378-5p induced cell cycle arrest and promoted apoptosis in CRC cells. A luciferase reporter assay indicated that BRAF was a direct target of miR-378-5p. Western blot and qRT-PCR analysis indicated that BRAF was significantly down-regulated by miR-378-5p in CRC cells. Moreover, miR-378-5p was negatively associated with BRAF in CRC tissues compared to adjacent non-tumor tissues. These results demonstrate that down-regulation of miR-378-5p promotes CRC cells growth by targeting BRAF and restoration of their levels is a potentially promising therapeutic in CRC.
    Cancer Cell International 12/2015; 15(1). DOI:10.1186/s12935-015-0192-2 · 1.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of endogenous protoporphyrin IX generated after administration of 5-aminolaevulinic acid (ALA) has led to many applications in Photodynamic Therapy (PDT). However the bioavailability of ALA is limited by its hydrophilic properties and limited cell uptake. A promising approach to optimize the efficacy of ALA-PDT is to deliver ALA in the form of prodrugs to mask its hydrophilic nature. The aim of this work was to evaluate the potential of two ALA dipeptide derivatives, N-acetyl terminated leucinyl-ALA (AcLeuALAMe) and phenylalanyl-ALA (AcPheALAMe), for their use in PDT of cancer, by investigating the generation of protoporphyrin IX in an oncogenic cell line (PAM212-Ras), and in a subcutaneous tumour model. In our in vitro studies, both derivatives were more effective than ALA in PDT treatment, at inducing the same protoporphyrin IX levels but at 50 to 100-fold lower concentrations, with the phenylalanyl derivative being the most effective. The efficient release of ALA from AcPheALAMe appears to be consistent with the reported substrate and inhibitor preferences of acylpeptide hydrolase (APEH). In vivo studies revealed that topical application of the peptide prodrug AcPheALAMe gave greater selectivity than with ALA itself, and induced tumour photodamage, whereas systemic administration improved ALA-induced porphyrin generation in terms of equivalent doses administered, without induction of toxic effects. Our data support the possibility of employing particularly AcPheALAMe both for topical treatment of basal cell carcinomas, and for systemic administration. Further chemical fine-tuning of this prodrug template should yield additional compounds for enhanced ALA-PDT with potential for translation to the clinic. Copyright © 2014, American Association for Cancer Research.
    Molecular Cancer Therapeutics 12/2014; DOI:10.1158/1535-7163.MCT-13-1084 · 6.11 Impact Factor